EMA Decision Time For GSK’s RSV Older Adult Vaccine & Roche’s Glofitamab For LBCL
Executive Summary
A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.
You may also be interested in...
EMA OKs Seven New Drugs Including First RSV Vaccine For Older Adults
GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.
Strapped For Cash GenSight Eyes Survival Options
The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.